Loquintha Vital
Nurse Practitioner · Ventura, CANPI 1790989630
Payments from drug & device makers
Across 152 payments — averaging $89.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Novo Nordisk$2K
- Lilly USA, LLC$761
- AstraZeneca$692
- AbbVie$643
- Amgen$452
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$6,33746%
- Food & beverage$7,24853%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $6,673 |
| Novo Nordisk | 40 | $1,775 |
| Lilly USA, LLC | 25 | $761 |
| AstraZeneca | 6 | $692 |
| AbbVie | 6 | $643 |
| Amgen | 10 | $452 |
| Abbott | 4 | $378 |
| Inspire Medical Systems, Inc. | 2 | $261 |
| Mannkind Corporation | 13 | $198 |
| Bayer | 6 | $195 |
| Inari Medical, Inc. | 1 | $167 |
| Sanofi-aventis U.S. LLC | 2 | $164 |
| Edwards Lifesciences | 1 | $154 |
| Silk Road Medical, Inc. | 1 | $150 |
| Nevro Corp. | 5 | $149 |
| Acadia Pharmaceuticals Inc | 1 | $121 |
| Xeris Pharmaceuticals, Inc. | 2 | $113 |
| Idorsia Pharmaceuticals US Inc | 1 | $112 |
| Gilead | 1 | $103 |
| Boston Scientific | 1 | $101 |
| Heartflow, Inc. | 1 | $61 |
| Endogastric Solutions, Inc | 1 | $52 |
| Dexcom, Inc. | 1 | $28 |
| Verrica Pharmaceuticals Inc. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Organon | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| GSK | 1 | $21 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 770G System$5,341
- MINIMED 770G$996
- RYBELSUS$371
- Wegovy$242
- MOUNJARO$241
- Ozempic$240
- FARXIGA$223
- FLOWTRIEVER CATHETER, S$167
- CT THROMBECTOMY SYSTEM KIT$167
- SAPIEN 3 Ultra RESILIA$154
- ENROUTE Transcarotid Stent$150
- ENROUTE Transcarotid Neuroprotection System$150
- Inspire$141
- FREESTYLE LIBRE 3$129
- EVENITY$125
- LOKELMA$125
- BREZTRI$125
- KRYSTEXXA$124
- PROCLAIM$124
- Mavyret$122
How this compares
$13,645 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 173 | $198,013 |
| Tresiba Flextouch U-100Insulin Degludec | 188 | $122,034 |
| JardianceEmpagliflozin | 87 | $68,204 |
| TrulicityDulaglutide | 51 | $54,293 |
| JanuviaSitagliptin Phosphate | 54 | $52,167 |
| FarxigaDapagliflozin Propanediol | 67 | $47,896 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 33 | $39,399 |
| MounjaroTirzepatide | 30 | $30,748 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $26,153 |
| RybelsusSemaglutide | 12 | $16,777 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $16,169 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $15,358 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $14,649 |
| VascepaIcosapent Ethyl | 18 | $10,719 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $9,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $1,775 | $254,189218 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $761 | $85,04181 claims |
| Boehringer IngelheimJardiance | $24 | $68,20487 claims |
| AstraZenecaFarxiga | $692 | $47,89667 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $164 | $14,64917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Ventura
- Beck EspirituVentura$155K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.